



Response Under 37 C.F.R. § 1.116
Expedited Procedure
Examining Group:1621

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mark E. Duggan et al.

Serial No. : 10/550,968

Case No. 21298P

Filed : September 26, 2005

Art Unit:

1621

Examiner:

Shailendra Kumar

FOR : BENZAMIDE MODULATORS OF METABOTROPIC
GLUTAMATE RECEPTORS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. §1.116

Sir:

With reference to the Official action of April 29, 2008, made final, for which a response is permitted by July 29, 2008, the Applicants respectfully request reconsideration of the application in view of the following amendments and remarks in the hope that they will place the application in condition for allowance or at least in better condition for appeal. Any additional fees associated with this Response may be charged to Merck Deposit Account No. 13-2755.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this response. **Remarks** begin on page 14 of this response.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

ON THE DATE APPEARING BELOW:

BY:

J. C. O'Neil

DATE: JULY 29, 2008